Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy
Summary Purpose: Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA have not been defined. Methods: We analyzed GADA with a radioimmunoassay in sera of 253 well‐characterized patients with epil...
Saved in:
| Published in | Epilepsia (Copenhagen) Vol. 51; no. 5; pp. 760 - 767 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.05.2010
Wiley-Blackwell |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary
Purpose: Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA have not been defined.
Methods: We analyzed GADA with a radioimmunoassay in sera of 253 well‐characterized patients with epilepsy and 200 control subjects. The positive samples were confirmed by immunohistochemistry and western blotting (WB). Sera were screened for other autoantibodies.
Results: GADA were detected in 15 patients (5.9%) and in three control subjects (1.5%) (p = 0.026). Seven patients (2.8%) had high GADA titers [≥1,000 relative units (RUs)/ml], six of whom had temporal lobe epilepsy (TLE). All three GADA‐positive control subjects had low titers. Two of the five patients with high GADA titers and available cerebrospinal fluid (CSF) samples had intrathecal synthesis (IS) of GADA; one patient had CSF oligoclonal bands. The prevalence of increased levels of GADA tended to be higher in patients with TLE than in patients with extra‐TLE [odds ratio (OR) 1.32, 95% confidence interval (CI) 0.39–4.42; p = 0.657]. The patients with high GADA titers had significantly higher number of other autoantibodies compared to the patients with low GADA titers (p = 0.001) and the patients with normal GADA (p < 0.001).
Discussion: High GADA titers were present in a subgroup of patients; close to 90% had TLE. The immunologic profile of these patients suggests that the most probable origin of their epilepsy is autoimmune. A positive IS of GADA may be a marker of an ongoing immune response that could identify those patients in whom a trial with immunosuppressive therapy might be warranted. |
|---|---|
| AbstractList | Purpose:
Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA have not been defined.
Methods:
We analyzed GADA with a radioimmunoassay in sera of 253 well‐characterized patients with epilepsy and 200 control subjects. The positive samples were confirmed by immunohistochemistry and western blotting (WB). Sera were screened for other autoantibodies.
Results:
GADA were detected in 15 patients (5.9%) and in three control subjects (1.5%) (p = 0.026). Seven patients (2.8%) had high GADA titers [≥1,000 relative units (RUs)/ml], six of whom had temporal lobe epilepsy (TLE). All three GADA‐positive control subjects had low titers. Two of the five patients with high GADA titers and available cerebrospinal fluid (CSF) samples had intrathecal synthesis (IS) of GADA; one patient had CSF oligoclonal bands. The prevalence of increased levels of GADA tended to be higher in patients with TLE than in patients with extra‐TLE [odds ratio (OR) 1.32, 95% confidence interval (CI) 0.39–4.42; p = 0.657]. The patients with high GADA titers had significantly higher number of other autoantibodies compared to the patients with low GADA titers (p = 0.001) and the patients with normal GADA (p < 0.001).
Discussion:
High GADA titers were present in a subgroup of patients; close to 90% had TLE. The immunologic profile of these patients suggests that the most probable origin of their epilepsy is autoimmune. A positive IS of GADA may be a marker of an ongoing immune response that could identify those patients in whom a trial with immunosuppressive therapy might be warranted. SummaryPurpose:Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA have not been defined.Methods:We analyzed GADA with a radioimmunoassay in sera of 253 well-characterized patients with epilepsy and 200 control subjects. The positive samples were confirmed by immunohistochemistry and western blotting (WB). Sera were screened for other autoantibodies.Results:GADA were detected in 15 patients (5.9%) and in three control subjects (1.5%) (p = 0.026). Seven patients (2.8%) had high GADA titers [ greater than or equal to 1,000 relative units (RUs)-ml], six of whom had temporal lobe epilepsy (TLE). All three GADA-positive control subjects had low titers. Two of the five patients with high GADA titers and available cerebrospinal fluid (CSF) samples had intrathecal synthesis (IS) of GADA; one patient had CSF oligoclonal bands. The prevalence of increased levels of GADA tended to be higher in patients with TLE than in patients with extra-TLE [odds ratio (OR) 1.32, 95% confidence interval (CI) 0.39-4.42; p = 0.657]. The patients with high GADA titers had significantly higher number of other autoantibodies compared to the patients with low GADA titers (p = 0.001) and the patients with normal GADA (p < 0.001).Discussion:High GADA titers were present in a subgroup of patients; close to 90% had TLE. The immunologic profile of these patients suggests that the most probable origin of their epilepsy is autoimmune. A positive IS of GADA may be a marker of an ongoing immune response that could identify those patients in whom a trial with immunosuppressive therapy might be warranted. Summary Purpose: Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA have not been defined. Methods: We analyzed GADA with a radioimmunoassay in sera of 253 well‐characterized patients with epilepsy and 200 control subjects. The positive samples were confirmed by immunohistochemistry and western blotting (WB). Sera were screened for other autoantibodies. Results: GADA were detected in 15 patients (5.9%) and in three control subjects (1.5%) (p = 0.026). Seven patients (2.8%) had high GADA titers [≥1,000 relative units (RUs)/ml], six of whom had temporal lobe epilepsy (TLE). All three GADA‐positive control subjects had low titers. Two of the five patients with high GADA titers and available cerebrospinal fluid (CSF) samples had intrathecal synthesis (IS) of GADA; one patient had CSF oligoclonal bands. The prevalence of increased levels of GADA tended to be higher in patients with TLE than in patients with extra‐TLE [odds ratio (OR) 1.32, 95% confidence interval (CI) 0.39–4.42; p = 0.657]. The patients with high GADA titers had significantly higher number of other autoantibodies compared to the patients with low GADA titers (p = 0.001) and the patients with normal GADA (p < 0.001). Discussion: High GADA titers were present in a subgroup of patients; close to 90% had TLE. The immunologic profile of these patients suggests that the most probable origin of their epilepsy is autoimmune. A positive IS of GADA may be a marker of an ongoing immune response that could identify those patients in whom a trial with immunosuppressive therapy might be warranted. Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA have not been defined.PURPOSEGlutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA have not been defined.We analyzed GADA with a radioimmunoassay in sera of 253 well-characterized patients with epilepsy and 200 control subjects. The positive samples were confirmed by immunohistochemistry and western blotting (WB). Sera were screened for other autoantibodies.METHODSWe analyzed GADA with a radioimmunoassay in sera of 253 well-characterized patients with epilepsy and 200 control subjects. The positive samples were confirmed by immunohistochemistry and western blotting (WB). Sera were screened for other autoantibodies.GADA were detected in 15 patients (5.9%) and in three control subjects (1.5%) (p = 0.026). Seven patients (2.8%) had high GADA titers [>or=1,000 relative units (RUs)/ml], six of whom had temporal lobe epilepsy (TLE). All three GADA-positive control subjects had low titers. Two of the five patients with high GADA titers and available cerebrospinal fluid (CSF) samples had intrathecal synthesis (IS) of GADA; one patient had CSF oligoclonal bands. The prevalence of increased levels of GADA tended to be higher in patients with TLE than in patients with extra-TLE [odds ratio (OR) 1.32, 95% confidence interval (CI) 0.39-4.42; p = 0.657]. The patients with high GADA titers had significantly higher number of other autoantibodies compared to the patients with low GADA titers (p = 0.001) and the patients with normal GADA (p < 0.001).RESULTSGADA were detected in 15 patients (5.9%) and in three control subjects (1.5%) (p = 0.026). Seven patients (2.8%) had high GADA titers [>or=1,000 relative units (RUs)/ml], six of whom had temporal lobe epilepsy (TLE). All three GADA-positive control subjects had low titers. Two of the five patients with high GADA titers and available cerebrospinal fluid (CSF) samples had intrathecal synthesis (IS) of GADA; one patient had CSF oligoclonal bands. The prevalence of increased levels of GADA tended to be higher in patients with TLE than in patients with extra-TLE [odds ratio (OR) 1.32, 95% confidence interval (CI) 0.39-4.42; p = 0.657]. The patients with high GADA titers had significantly higher number of other autoantibodies compared to the patients with low GADA titers (p = 0.001) and the patients with normal GADA (p < 0.001).High GADA titers were present in a subgroup of patients; close to 90% had TLE. The immunologic profile of these patients suggests that the most probable origin of their epilepsy is autoimmune. A positive IS of GADA may be a marker of an ongoing immune response that could identify those patients in whom a trial with immunosuppressive therapy might be warranted.DISCUSSIONHigh GADA titers were present in a subgroup of patients; close to 90% had TLE. The immunologic profile of these patients suggests that the most probable origin of their epilepsy is autoimmune. A positive IS of GADA may be a marker of an ongoing immune response that could identify those patients in whom a trial with immunosuppressive therapy might be warranted. Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA have not been defined. We analyzed GADA with a radioimmunoassay in sera of 253 well-characterized patients with epilepsy and 200 control subjects. The positive samples were confirmed by immunohistochemistry and western blotting (WB). Sera were screened for other autoantibodies. GADA were detected in 15 patients (5.9%) and in three control subjects (1.5%) (p = 0.026). Seven patients (2.8%) had high GADA titers [>or=1,000 relative units (RUs)/ml], six of whom had temporal lobe epilepsy (TLE). All three GADA-positive control subjects had low titers. Two of the five patients with high GADA titers and available cerebrospinal fluid (CSF) samples had intrathecal synthesis (IS) of GADA; one patient had CSF oligoclonal bands. The prevalence of increased levels of GADA tended to be higher in patients with TLE than in patients with extra-TLE [odds ratio (OR) 1.32, 95% confidence interval (CI) 0.39-4.42; p = 0.657]. The patients with high GADA titers had significantly higher number of other autoantibodies compared to the patients with low GADA titers (p = 0.001) and the patients with normal GADA (p < 0.001). High GADA titers were present in a subgroup of patients; close to 90% had TLE. The immunologic profile of these patients suggests that the most probable origin of their epilepsy is autoimmune. A positive IS of GADA may be a marker of an ongoing immune response that could identify those patients in whom a trial with immunosuppressive therapy might be warranted. |
| Author | Saiz, Albert Liimatainen, Suvi Kharazmi, Elham Sabater, Lidia Peltola, Jukka Fallah, Mahdi Knip, Mikael Haapala, Anna‐Maija Dastidar, Prasun Peltola, Maria |
| Author_xml | – sequence: 1 givenname: Suvi surname: Liimatainen fullname: Liimatainen, Suvi – sequence: 2 givenname: Maria surname: Peltola fullname: Peltola, Maria – sequence: 3 givenname: Lidia surname: Sabater fullname: Sabater, Lidia – sequence: 4 givenname: Mahdi surname: Fallah fullname: Fallah, Mahdi – sequence: 5 givenname: Elham surname: Kharazmi fullname: Kharazmi, Elham – sequence: 6 givenname: Anna‐Maija surname: Haapala fullname: Haapala, Anna‐Maija – sequence: 7 givenname: Prasun surname: Dastidar fullname: Dastidar, Prasun – sequence: 8 givenname: Mikael surname: Knip fullname: Knip, Mikael – sequence: 9 givenname: Albert surname: Saiz fullname: Saiz, Albert – sequence: 10 givenname: Jukka surname: Peltola fullname: Peltola, Jukka |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22781150$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19817821$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUFvFCEYhompsdvqXzBcjKeZfsAwwEETs6napIke9OCJMAxUNiwzDrPp7r-Xcdea9GK58CU830vyPhfoLA3JIYQJ1KScq01NOJUVIa2oKYCqgTLK6_0ztHp4OEMrAMIqxSWco4ucNwAgWsFeoHOiJBGSkhX6sY4hBWsizuEuBV_GZB0ePL6Lu9lsg8XGhh73zpqpG_aHaLLDJs2hG_rgMg4Jj2YOLs0Z34f5J3ZjiG7Mh5fouTcxu1en-xJ9_3j9bf25uv3y6Wb94bayjQReib7tuk4RTxsnrbegJBe-Jcb3wgDQnlFKLTWeScGBe95IoxrRNB1zHXGEXaK3x9xxGn7tXJ71NmTrYjTJDbusRdNSpZhQ_ycZo1ICo4V8fSJ33db1epzC1kwH_be3Arw5ASaX8vxUWgv5gaNUSEI4FE4eOTsNOU_O_4sCvajUG70Y04sxvajUf1TqfVl9_2jVhrk0PaR5MiE-JeDdMeC-CDk8-WN9_fVmmdhvyz23FA |
| CODEN | EPILAK |
| CitedBy_id | crossref_primary_10_11648_j_iji_20241202_12 crossref_primary_10_1111_apa_14910 crossref_primary_10_1259_bjr_20170869 crossref_primary_10_1111_ene_12261 crossref_primary_10_1111_epi_14534 crossref_primary_10_1016_j_spen_2014_08_002 crossref_primary_10_1001_jamaneurol_2021_3113 crossref_primary_10_1097_MD_0000000000019601 crossref_primary_10_1097_NRL_0b013e318247b87d crossref_primary_10_1007_s10309_020_00363_3 crossref_primary_10_1097_WCO_0b013e3283446f05 crossref_primary_10_1212_CON_0000000000001079 crossref_primary_10_1002_acn3_520 crossref_primary_10_1177_1550059418800867 crossref_primary_10_1186_s13023_018_0787_5 crossref_primary_10_1016_j_yebeh_2014_04_022 crossref_primary_10_2106_JBJS_CC_20_00378 crossref_primary_10_1007_s00125_016_3929_0 crossref_primary_10_1016_j_seizure_2018_05_004 crossref_primary_10_1007_s00115_012_3605_7 crossref_primary_10_1016_j_eplepsyres_2013_12_015 crossref_primary_10_1371_journal_pone_0241289 crossref_primary_10_3390_brainsci13101361 crossref_primary_10_1111_j_1468_1331_2011_03609_x crossref_primary_10_3390_brainsci11030392 crossref_primary_10_1007_s00415_020_09814_3 crossref_primary_10_1212_NXI_0000000000200034 crossref_primary_10_1007_s00415_020_09807_2 crossref_primary_10_1530_EJE_12_0699 crossref_primary_10_1017_S0317167100013147 crossref_primary_10_1007_s11940_012_0212_7 crossref_primary_10_1017_S0317167100015444 crossref_primary_10_1016_j_jns_2014_08_024 crossref_primary_10_1007_s10072_011_0566_8 crossref_primary_10_1136_bcr_2024_260503 crossref_primary_10_1080_1744666X_2017_1327351 crossref_primary_10_1097_WCO_0000000000000449 crossref_primary_10_1016_j_jns_2022_120540 crossref_primary_10_3390_brainsci13020369 crossref_primary_10_1111_j_1750_3639_2012_00580_x crossref_primary_10_1016_j_neurol_2018_07_006 crossref_primary_10_1177_1756286420952901 crossref_primary_10_1016_j_yebeh_2011_03_038 crossref_primary_10_1111_epi_13784 crossref_primary_10_1016_j_eplepsyres_2015_05_008 crossref_primary_10_1016_j_jneuroim_2013_08_001 crossref_primary_10_20515_otd_1167517 crossref_primary_10_3390_ijms21103701 crossref_primary_10_1111_cen3_12154 crossref_primary_10_1016_j_eplepsyres_2013_02_009 crossref_primary_10_1016_j_yebeh_2018_03_004 crossref_primary_10_5698_1535_7511_13_1_24 crossref_primary_10_3390_bios14110543 crossref_primary_10_5698_1535_7511_17_3_134 crossref_primary_10_1111_j_1528_1167_2011_03031_x crossref_primary_10_1038_s41582_020_0359_x crossref_primary_10_1177_0883073813500527 crossref_primary_10_1016_j_seizure_2014_04_009 crossref_primary_10_1016_j_epag_2013_05_002 crossref_primary_10_1212_WNL_0000000000000383 crossref_primary_10_1016_j_jneuroim_2020_577189 crossref_primary_10_1016_j_jneuroim_2015_11_012 crossref_primary_10_1016_j_pediatrneurol_2012_06_013 crossref_primary_10_1002_epi4_12395 crossref_primary_10_1016_j_ejpn_2012_11_003 crossref_primary_10_1111_pcn_12543 crossref_primary_10_3389_fncel_2023_1129907 crossref_primary_10_1007_s13311_019_00750_3 crossref_primary_10_1016_j_autrev_2015_01_002 crossref_primary_10_1016_j_eplepsyres_2017_06_008 crossref_primary_10_1007_s00415_024_12210_w crossref_primary_10_1136_bcr_2020_237913 crossref_primary_10_1016_j_yebeh_2018_01_021 crossref_primary_10_4103_nsn_nsn_226_21 crossref_primary_10_1111_j_1468_1331_2011_03641_x crossref_primary_10_1159_000369058 crossref_primary_10_1136_jnnp_2020_325275 crossref_primary_10_1007_s11892_015_0588_3 crossref_primary_10_1007_s00415_015_8002_2 crossref_primary_10_1038_s41598_017_06294_w crossref_primary_10_1007_s13760_017_0796_5 crossref_primary_10_3389_fneur_2023_1211812 crossref_primary_10_1016_j_jneuroim_2019_577063 crossref_primary_10_1016_j_jns_2019_06_021 crossref_primary_10_1177_1535759720949238 crossref_primary_10_1007_s00115_011_3257_z crossref_primary_10_1016_j_eplepsyres_2011_02_003 crossref_primary_10_1016_j_seizure_2020_05_008 crossref_primary_10_1007_s11910_013_0348_1 crossref_primary_10_1016_j_jneuroim_2020_577324 crossref_primary_10_1155_2020_8454532 crossref_primary_10_1016_j_yebeh_2012_08_008 crossref_primary_10_3389_fncel_2016_00130 crossref_primary_10_1016_j_eplepsyres_2012_06_002 crossref_primary_10_1080_00207454_2017_1389928 crossref_primary_10_1111_epi_12127 crossref_primary_10_2217_bmm_13_142 crossref_primary_10_1093_brain_awac404 crossref_primary_10_1111_epi_12528 |
| Cites_doi | 10.1111/j.1468-1331.2004.00933.x 10.1053/seiz.2002.0593 10.1212/01.wnl.0000187129.66353.13 10.1073/pnas.94.25.14060 10.1111/j.1468-1331.2008.02373.x 10.1126/science.8036512 10.1212/WNL.49.4.1026 10.1002/ana.410440209 10.1080/08916930701619565 10.1056/NEJM200002033420503 10.1007/s001250051067 10.1007/s102380300013 10.1111/j.1528-1157.1996.tb00527.x 10.1016/j.jneuroim.2008.05.015 10.1136/jnnp.2006.089268 10.1136/jnnp.41.5.458 10.1212/WNL.55.1.46 10.1016/S0920-1211(00)00180-7 10.1080/17402520400001736 10.1001/archneur.58.2.225 10.1038/nm0296-148 10.2169/internalmedicine.44.1174 10.1212/01.WNL.0000106821.83436.59 10.1002/ana.21123 10.1002/ana.410360419 10.1111/j.1528-1157.1989.tb05316.x 10.1212/WNL.57.5.780 10.1084/jem.178.6.2097 10.1016/S0165-5728(02)00261-8 10.1586/14737175.8.7.1141 10.1093/brain/awn183 10.1111/j.1528-1167.2007.01500.x 10.1056/NEJM198804213181602 10.1542/peds.109.3.e50 10.1016/j.eplepsyres.2006.06.003 10.1056/NEJM199005313222202 10.1111/j.1528-1157.1997.tb01226.x 10.1038/347151a0 10.1016/S0140-6736(05)79192-3 10.7326/0003-4819-131-7-199910050-00008 |
| ContentType | Journal Article |
| Copyright | Wiley Periodicals, Inc. © 2009 International League Against Epilepsy 2015 INIST-CNRS |
| Copyright_xml | – notice: Wiley Periodicals, Inc. © 2009 International League Against Epilepsy – notice: 2015 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7TK |
| DOI | 10.1111/j.1528-1167.2009.02325.x |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Neurosciences Abstracts |
| DatabaseTitleList | CrossRef Neurosciences Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1528-1167 |
| EndPage | 767 |
| ExternalDocumentID | 19817821 22781150 10_1111_j_1528_1167_2009_02325_x EPI2325 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 24P 29G 2WC 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAGKA AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIVO ABJNI ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FYBCS G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OHT OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI TR2 UB1 V8K V9Y VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAFWJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7X8 7TK |
| ID | FETCH-LOGICAL-c4805-7d6bbb91f24e8cfc09857f61afd7a002d3222c2af387505f548a94744b3eb1e13 |
| IEDL.DBID | DR2 |
| ISSN | 0013-9580 1528-1167 |
| IngestDate | Thu Jul 10 22:12:37 EDT 2025 Fri Jul 11 00:08:50 EDT 2025 Mon Jul 21 05:36:26 EDT 2025 Mon Jul 21 09:14:07 EDT 2025 Thu Apr 24 23:05:23 EDT 2025 Tue Jul 01 03:56:16 EDT 2025 Wed Jan 22 16:12:49 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Human Glutamic acid Nervous system diseases Aminoacid Central nervous system disease Complex partial epilepsy Temporal lobe epilepsy Polyendocrinopathy Glutamic acid decarboxylase antibody Cerebral disorder Immune system |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4805-7d6bbb91f24e8cfc09857f61afd7a002d3222c2af387505f548a94744b3eb1e13 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1528-1167.2009.02325.x |
| PMID | 19817821 |
| PQID | 733288032 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_746299379 proquest_miscellaneous_733288032 pubmed_primary_19817821 pascalfrancis_primary_22781150 crossref_primary_10_1111_j_1528_1167_2009_02325_x crossref_citationtrail_10_1111_j_1528_1167_2009_02325_x wiley_primary_10_1111_j_1528_1167_2009_02325_x_EPI2325 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | May 2010 |
| PublicationDateYYYYMMDD | 2010-05-01 |
| PublicationDate_xml | – month: 05 year: 2010 text: May 2010 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Malden, MA – name: United States |
| PublicationTitle | Epilepsia (Copenhagen) |
| PublicationTitleAlternate | Epilepsia |
| PublicationYear | 2010 |
| Publisher | Blackwell Publishing Ltd Wiley-Blackwell |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley-Blackwell |
| References | 2006; 71 1990; 347 2004; 62 2002; 131 2000; 42 2002; 11 2008; 8 2008; 13 2005; 65 1997; 49 1998; 41 1990; 322 1996; 37 2007; 78 2005; 44 1998; 44 1989; 30 2004; 11 1994; 265 1997; 94 1978; 41 2000; 55 2008; 49 1999; 131 2003; 3 1994; 36 1997; 38 2007; 61 2000; 342 2008; 41 2002; 109 2001; 57 1996; 2 1988; 318 2001; 58 2008; 131 2009; 16 2005; 12 1993; 178 1998; 8 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_30_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_21_1 e_1_2_6_20_1 e_1_2_6_41_1 e_1_2_6_40_1 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_22_1 e_1_2_6_29_1 e_1_2_6_28_1 e_1_2_6_27_1 e_1_2_6_26_1 |
| References_xml | – volume: 57 start-page: 780 year: 2001 end-page: 784 article-title: Stiff‐person syndrome. Quantification, specificity, and intrathecal synthesis of GAD65 antibodies publication-title: Neurology – volume: 42 start-page: 191 year: 2000 end-page: 195 article-title: Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study publication-title: Epilepsy Res – volume: 131 start-page: 2553 year: 2008 end-page: 2563 article-title: Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association publication-title: Brain – volume: 347 start-page: 151 year: 1990 end-page: 156 article-title: Identification of the 64K autoantigen in insulin‐dependent diabetes as the GABA‐synthesizing enzyme glutamic acid decarboxylase publication-title: Nature – volume: 41 start-page: 458 year: 1978 end-page: 462 article-title: Stiff‐man syndrome associated with nocturnal myoclonus and epilepsy publication-title: J Neurol Neurosurg Psychiatry – volume: 342 start-page: 314 year: 2000 end-page: 319 article-title: Early identification of refractory epilepsy publication-title: N Engl J Med – volume: 41 start-page: 1293 year: 1998 end-page: 1297 article-title: Autoantibodies associated with Type I diabetes mellitus persist after diagnosis in children publication-title: Diabetologia – volume: 322 start-page: 1555 year: 1990 end-page: 1560 article-title: Autoantibodies to GABA‐ergic neurons and pancreatic beta cells in stiff‐man syndrome publication-title: N Engl J Med – volume: 49 start-page: 914 year: 2008 end-page: 920 article-title: Cyclophosphamide for anti‐GAD antibody‐positive refractory status epilepticus publication-title: Epilepsia – volume: 11 start-page: 77 year: 2002 end-page: 84 article-title: Refractory epilepsy: a progressive, intractable but preventable condition? publication-title: Seizure – volume: 131 start-page: 179 year: 2002 end-page: 185 article-title: Antibodies against GluR3 peptides are not specific for Rasmussen’s encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures publication-title: J Neuroimmunol – volume: 178 start-page: 2097 year: 1993 end-page: 2106 article-title: Identification of a dominant epitope of glutamic acid decarboxylase (GAD‐65) recognized by autoantibodies in stiff‐man syndrome publication-title: J Exp Med – volume: 49 start-page: 1026 year: 1997 end-page: 1030 article-title: Autoantibodies to glutamic acid decarboxylase in three patients with cerebellar ataxia, late‐onset insulin‐dependent diabetes mellitus, and polyendocrine autoimmunity publication-title: Neurology – volume: 78 start-page: 187 year: 2007 end-page: 189 article-title: Epilepsy and cerebellar ataxia associated with anti‐glutamic acid decarboxylase antibodies publication-title: J Neurol Neurosurg Psychiatry – volume: 36 start-page: 665 year: 1994 end-page: 667 article-title: Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy publication-title: Ann Neurol – volume: 265 start-page: 648 year: 1994 end-page: 651 article-title: Autoantibodies to glutamate receptor GluR3 in Rasmussen’s encephalitis publication-title: Science – volume: 12 start-page: 294 year: 2005 end-page: 299 article-title: Antigenic differences between neurological and diabetic patients with anti‐glutamic acid decarboxylase antibodies publication-title: Eur J Neurol – volume: 44 start-page: 1174 year: 2005 end-page: 1177 article-title: Type 1 diabetes mellitus and drug‐resistant epilepsy: presence of high titer of anti‐glutamic acid decarboxylase autoantibodies in serum and cerebrospinal fluid publication-title: Intern Med – volume: 65 start-page: 1730 year: 2005 end-page: 1736 article-title: Serum antibodies in epilepsy and seizure‐associated disorders publication-title: Neurology – volume: 58 start-page: 225 year: 2001 end-page: 230 article-title: Cerebellar ataxia with anti‐glutamic acid decarboxylase antibodies: study of 14 patients publication-title: Arch Neurol – volume: 8 start-page: 457 year: 1998 article-title: Temporal‐lobe epilepsy associated with glutamic‐acid‐decarboxylase autoantibodies publication-title: Lancet – volume: 13 start-page: 155 year: 2008 end-page: 159 article-title: Non‐paraneoplastic limbic encephalitis associated with anti‐glutamic acid decarboxylase antibodies publication-title: J Neuroimmunol – volume: 8 start-page: 1141 year: 2008 end-page: 1160 article-title: Autoantibodies to glutamate receptors can damage the brain in epilepsy, systemic lupus erythematosus and encephalitis publication-title: Expert Rev Neurother – volume: 94 start-page: 14060 year: 1997 end-page: 14065 article-title: Epilepsy in mice deficient in the 65‐kDa isoform of glutamic acid decarboxylase publication-title: Proc Natl Acad Sci U S A – volume: 71 start-page: 135 year: 2006 end-page: 141 article-title: Antibodies to voltage‐gated potassium and calcium channels in epilepsy publication-title: Epilepsy Res – volume: 30 start-page: 389 year: 1989 end-page: 399 article-title: Proposal for revised classification of epilepsies and epileptic syndromes publication-title: Epilepsia – volume: 41 start-page: 66 year: 2008 end-page: 73 article-title: Increased spontaneous activity of a network of hippocampal neurons in culture caused by suppression of inhibitory potentials mediated by anti‐gad antibodies publication-title: Autoimmunity – volume: 62 start-page: 517 year: 2004 end-page: 518 article-title: Antiphospholipid and glutamic acid decarboxylase antibodies in patients with focal epilepsy publication-title: Neurology – volume: 318 start-page: 1012 year: 1988 end-page: 1020 article-title: Autoantibodies to glutamic acid decarboxylase in a patient with stiff‐man syndrome, epilepsy, and type I diabetes mellitus publication-title: N Engl J Med – volume: 131 start-page: 522 year: 1999 end-page: 530 article-title: The stiff‐person syndrome: an autoimmune disorder affecting neurotransmission of gamma‐aminobutyric acid publication-title: Ann Intern Med – volume: 2 start-page: 148 year: 1996 end-page: 153 article-title: The clinical significance of an autoimmune response against glutamic acid decarboxylase publication-title: Nat Med – volume: 3 start-page: 32 year: 2003 end-page: 36 article-title: Anticardiolipin, glutamic acid decarboxylase, and antinuclear antibodies in epileptic patients publication-title: Clin Exp Med – volume: 109 start-page: E50 year: 2002 article-title: Type 1 diabetes mellitus and epilepsia partialis continua in a 6‐year‐old boy with elevated anti‐GAD65 antibodies publication-title: Pediatrics – volume: 55 start-page: 46 year: 2000 end-page: 50 article-title: Autoantibodies to glutamic acid decarboxylase in patients with therapy‐resistant epilepsy publication-title: Neurology – volume: 61 start-page: 544 year: 2007 end-page: 551 article-title: Effects of anti‐glutamic acid decarboxylase antibodies associated with neurological diseases publication-title: Ann Neurol – volume: 38 start-page: 1255 year: 1997 end-page: 1256 article-title: Recommendations for neuroimaging of patients with epilepsy publication-title: Epilepsia – volume: 11 start-page: 241 year: 2004 end-page: 252 article-title: Autoimmune epilepsy: some epilepsy patients harbor autoantibodies to glutamate receptors and dsDNA on both sides of the blood‐brain barrier, which may kill neurons and decrease in brain fluids after hemispherotomy publication-title: Clin Dev Immunol – volume: 37 start-page: 922 year: 1996 end-page: 926 article-title: Cryptogenic partial epilepsies with anti‐GM1 antibodies: a new form of immune‐mediated epilepsy? publication-title: Epilepsia – volume: 44 start-page: 194 year: 1998 end-page: 201 article-title: Inhibition of gamma‐aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff‐man syndrome publication-title: Ann Neurol – volume: 16 start-page: 134 year: 2009 end-page: 141 article-title: The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures publication-title: Eur J Neurol – ident: e_1_2_6_38_1 doi: 10.1111/j.1468-1331.2004.00933.x – ident: e_1_2_6_17_1 doi: 10.1053/seiz.2002.0593 – ident: e_1_2_6_26_1 doi: 10.1212/01.wnl.0000187129.66353.13 – ident: e_1_2_6_14_1 doi: 10.1073/pnas.94.25.14060 – ident: e_1_2_6_20_1 doi: 10.1111/j.1468-1331.2008.02373.x – ident: e_1_2_6_30_1 doi: 10.1126/science.8036512 – ident: e_1_2_6_31_1 doi: 10.1212/WNL.49.4.1026 – ident: e_1_2_6_8_1 doi: 10.1002/ana.410440209 – ident: e_1_2_6_39_1 doi: 10.1080/08916930701619565 – ident: e_1_2_6_15_1 doi: 10.1056/NEJM200002033420503 – ident: e_1_2_6_33_1 doi: 10.1007/s001250051067 – ident: e_1_2_6_37_1 doi: 10.1007/s102380300013 – ident: e_1_2_6_3_1 doi: 10.1111/j.1528-1157.1996.tb00527.x – ident: e_1_2_6_25_1 doi: 10.1016/j.jneuroim.2008.05.015 – ident: e_1_2_6_40_1 doi: 10.1136/jnnp.2006.089268 – ident: e_1_2_6_24_1 doi: 10.1136/jnnp.41.5.458 – ident: e_1_2_6_29_1 doi: 10.1212/WNL.55.1.46 – ident: e_1_2_6_16_1 doi: 10.1016/S0920-1211(00)00180-7 – ident: e_1_2_6_10_1 doi: 10.1080/17402520400001736 – ident: e_1_2_6_12_1 doi: 10.1001/archneur.58.2.225 – ident: e_1_2_6_9_1 doi: 10.1038/nm0296-148 – ident: e_1_2_6_41_1 doi: 10.2169/internalmedicine.44.1174 – ident: e_1_2_6_34_1 doi: 10.1212/01.WNL.0000106821.83436.59 – ident: e_1_2_6_23_1 doi: 10.1002/ana.21123 – ident: e_1_2_6_27_1 doi: 10.1002/ana.410360419 – ident: e_1_2_6_5_1 doi: 10.1111/j.1528-1157.1989.tb05316.x – ident: e_1_2_6_7_1 doi: 10.1212/WNL.57.5.780 – ident: e_1_2_6_4_1 doi: 10.1084/jem.178.6.2097 – ident: e_1_2_6_22_1 doi: 10.1016/S0165-5728(02)00261-8 – ident: e_1_2_6_18_1 doi: 10.1586/14737175.8.7.1141 – ident: e_1_2_6_32_1 doi: 10.1093/brain/awn183 – ident: e_1_2_6_13_1 doi: 10.1111/j.1528-1167.2007.01500.x – ident: e_1_2_6_35_1 doi: 10.1056/NEJM198804213181602 – ident: e_1_2_6_28_1 doi: 10.1542/peds.109.3.e50 – ident: e_1_2_6_21_1 doi: 10.1016/j.eplepsyres.2006.06.003 – ident: e_1_2_6_36_1 doi: 10.1056/NEJM199005313222202 – ident: e_1_2_6_6_1 doi: 10.1111/j.1528-1157.1997.tb01226.x – ident: e_1_2_6_2_1 doi: 10.1038/347151a0 – ident: e_1_2_6_11_1 doi: 10.1016/S0140-6736(05)79192-3 – ident: e_1_2_6_19_1 doi: 10.7326/0003-4819-131-7-199910050-00008 |
| SSID | ssj0007673 |
| Score | 2.3573234 |
| Snippet | Summary
Purpose: Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy... Purpose: Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated... Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy associated with GADA... SummaryPurpose:Glutamic acid decarboxylase antibodies (GADAs) have been detected in patients with epilepsy, but the clinical determinants of epilepsy... |
| SourceID | proquest pubmed pascalfrancis crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 760 |
| SubjectTerms | Adolescent Adult Age Distribution Aged Anticonvulsants. Antiepileptics. Antiparkinson agents Autoantibodies - blood Autoantibodies - cerebrospinal fluid Autoantibodies - immunology Autoimmune Diseases - blood Autoimmune Diseases - diagnosis Autoimmune Diseases - immunology Biological and medical sciences Blotting, Western Epilepsy - blood Epilepsy - cerebrospinal fluid Epilepsy - immunology Epilepsy, Temporal Lobe - blood Epilepsy, Temporal Lobe - immunology Female Genetic Markers Glutamate Decarboxylase - blood Glutamate Decarboxylase - immunology Glutamic acid decarboxylase antibody Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Humans Immune system Immunohistochemistry Male Medical sciences Middle Aged Nervous system (semeiology, syndromes) Neurology Neuropharmacology Pharmacology. Drug treatments Polyendocrinopathies, Autoimmune - diagnosis Polyendocrinopathies, Autoimmune - immunology Polyendocrinopathy Radioimmunoassay Temporal lobe epilepsy |
| Title | Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1528-1167.2009.02325.x https://www.ncbi.nlm.nih.gov/pubmed/19817821 https://www.proquest.com/docview/733288032 https://www.proquest.com/docview/746299379 |
| Volume | 51 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEF-kDyKI39rUWvbB1xzZzWY_HqW0tEJFxEJ9CvspR2vuaO5A_eudSfauRooU8SGQh0yY3Z3Z-c3O7Awhb7VOYGh4LHVyqRTemdJ6zUolwZzHBh90FM8-yJNz8f6iucj5T3gXZqwPsT1wQ80Y9mtUcOv6qZI3HDwgJlUuOwngoJkhnsTULcRHn24qSSmZg82sLk2jq2lSz60_mliqh0vbw6SlsdvFbXB0im4H83T8mFxuBjZmpVzO1is38z__qPn4f0b-hDzKKJa-G8XuKbkXu2fk_lmO0z8nX3K50SuK-SGYjYTCRReJfgVJt9_mnlo_DzREb68dsAwYPlJY5LlbYFojnXc0V3ztKR4V07gEVpf9jxfk_Pjo8-FJmZs4lF7oqilVkM45wxIXUfvkK6MblSSzKSgL23HAUI_nNtXgOVVNAg_KGqGEcDWYkcjql2SnW3Rxl1BTOW9ZCCLFBChPOm5EDFIm7gJPui6I2ixY63OFc2y0cdX-5unAzLU4c9h_07TDzLXfC8K2lMuxyscdaA4mMrElxMvFiLMLQjdC0oLOYiDGdnGx7ltV1xz2zZr_5RMhOUJHU5BXo3zdMGY0A1zHCiIHKbkzx-3Rx1N82_tXwtfkwSZ5omL7ZGd1vY5vAJOt3MGgbb8A_Gwmsg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxQxEA9SQQXxW7t-1Dz4uscmm80mj6ItV-0VkRbqU0iyiRyee0fvDqp_vTO7uasrRYr4sLAPmyWZzGR-k0x-Q8gbpSI4Gh5yFV3MhXc6t16xvJbgzkOFDwaKk2M5PhUfzqqzVA4I78L0_BDbDTe0jG69RgPHDemhlVccQiAm68Q7CeigGgGgvIkFvpFI__3nSy6pWqbjZlbmulLFMK3nyj8NfNXdhV2C2GJf7-IqQDrEt52DOrhPZpuh9Xkp30brlRv5n3-wPv6nsT8g9xKQpW97zXtIboT2Ebk1SUf1j8mXxDg6o5gigglJqF90HulXUHb7feqp9dOGNsHbcwd9BhgfKMzz1M0xs5FOW5pIX5cUd4tpWEBfF8sfT8jpwf7Ju3Ge6jjkXqiiyutGOuc0i1wE5aMvtKrqKJmNTW1hRW7wtMdzG0sInooqQhBltaiFcCV4ksDKp2Snnbdhl1BdOG9Z04gYIgA96bgWoZEyctfwqMqM1JsZMz6RnGOtjZn5LdgByRmUHJbg1KaTnLnICNu2XPREH9doszdQim1DvF-MUDsjdKMlBswWz2JsG-brpanLksPSWfK_fCIkR_SoM_KsV7DLjmnFANqxjMhOTa7dY7P_6RDfnv9rw9fk9vhkcmSODo8_viB3NrkUBXtJdlbn6_AKINrK7XWm9wtshCrO |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhVAofT_cR6pDr14sWdbjWJosSduEUBpIT0bPsCT1muwutP31nbG9m7qEEkoPBh88RhrNaL7RjGYIeat1AkPDY66TS7nwzuTWa5YrCeY8Vvigo3h4JPdPxIfT6nTIf8K7MH19iM2BG2pGt1-jgrchjZW84uABMamGspMADqoJ4MnbQhYG2zjsfr4qJaXkEG1mZW4qXYyzeq7908hU3W3tAriW-nYX1-HRMbzt7NP0Pjlfz6xPSzmfrJZu4n_-UfTx_0z9Abk3wFj6rpe7h-RWbB6R7cMhUP-YfB3qjV5QTBDBdCSULjpP9AxE3X6beWr9LNAQvb10MGQA8ZHCKs_cHPMa6ayhQ8nXBcWzYhpbGGq7-PGEnEz3vrzfz4cuDrkXuqhyFaRzzrDERdQ--cLoSiXJbArKwn4cMNbjuU0luE5FlcCFskYoIVwJdiSy8inZauZNfE6oKZy3LASRYgKYJx03IgYpE3eBJ11mRK0XrPZDiXPstHFR_-bqAOdq5Bw24DR1x7n6e0bYhrLty3zcgGZnJBMbQrxdjEA7I3QtJDUoLUZibBPnq0WtypLDxlnyv3wiJEfsaDLyrJevq4EZzQDYsYzITkpuPOJ67_gA3178K-Ebsn28O60_HRx9fEnurBMpCvaKbC0vV_E14LOl2-kU7xe2sil9 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+significance+of+glutamic+acid+decarboxylase+antibodies+in+patients+with+epilepsy&rft.jtitle=Epilepsia+%28Copenhagen%29&rft.au=Liimatainen%2C+Suvi&rft.au=Peltola%2C+Maria&rft.au=Sabater%2C+Lidia&rft.au=Fallah%2C+Mahdi&rft.date=2010-05-01&rft.issn=0013-9580&rft.eissn=1528-1167&rft.volume=51&rft.issue=5&rft.spage=760&rft.epage=767&rft_id=info:doi/10.1111%2Fj.1528-1167.2009.02325.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1528_1167_2009_02325_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0013-9580&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0013-9580&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0013-9580&client=summon |